Drug Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Drug Name Blinatumomab
Trade Name Blincyto
Synonyms anti-CD19/anti-CD3 recombinant bispecific|monoclonal antibody MT103|MEDI-538
Drug Descriptions

Blincyto (blinatumomab) is a bispecific antibody that binds both CD19 on B-cells and the CD3 complex on T-cells, therefore facilitates T-cell mediated killing of CD19-expressing tumor cells (PMID: 26337639). Blincyto (blinatumomab) is FDA approved for the treatment of B-cell precursor acute lymphoblastic leukemia in adult and children negative for BCR-ABL1 (FDA.gov).

DrugClasses CD19 Antibody 9

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
Blinatumomab Blinatumomab 1 8
Blinatumomab + Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine Sulfate Blinatumomab Cyclophosphamide Dexamethasone Doxorubicin Vincristine Sulfate 0 1
Blinatumomab + Cytarabine + Dexamethasone + Methotrexate + Ponatinib Blinatumomab Cytarabine Dexamethasone Methotrexate Ponatinib 0 1
Blinatumomab + Dasatinib Blinatumomab Dasatinib 0 1
Blinatumomab + Dasatinib + Methotrexate Blinatumomab Dasatinib Methotrexate 0 1
Blinatumomab + Dexamethasone + Leucovorin Blinatumomab Dexamethasone Leucovorin 0 1
Blinatumomab + Dexamethasone + Leucovorin + Methotrexate Blinatumomab Dexamethasone Leucovorin Methotrexate 0 1
Blinatumomab + Dexamethasone + Methotrexate Blinatumomab Dexamethasone Methotrexate 0 1
Blinatumomab + Dexamethasone + Ponatinib Blinatumomab Dexamethasone Ponatinib 0 1
Blinatumomab + Ibrutinib Blinatumomab Ibrutinib 0 1
Blinatumomab + Inotuzumab ozogamicin Blinatumomab Inotuzumab ozogamicin 0 1
Blinatumomab + Ipilimumab + Nivolumab Blinatumomab Ipilimumab Nivolumab 0 1
Blinatumomab + Leucovorin + Methotrexate Blinatumomab Leucovorin Methotrexate 0 1
Blinatumomab + Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Blinatumomab Mercaptopurine Methotrexate Prednisone Vincristine Sulfate 0 1
Blinatumomab + Methotrexate Blinatumomab Methotrexate 0 1
Blinatumomab + Pembrolizumab Blinatumomab Pembrolizumab 0 4


Additional content available in CKB BOOST